Use access key #2 to skip to page content.
$5.64 -0.07 (-1.23%)
9/5/2008 4:00 PM

Exelixis, Inc. (EXEL)

CAPS Rating:
*****

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

View All Commentary (EXEL)

Recs

2

Avatar redbird67 (65.22) Submitted: 8/23/06 5:38 PM : Outperform Start Price: $8.10 EXEL Score: -26.36

Appears to have smart management. Uses development partnerships to spread the risk (and costs). Relationships with some large drug companies that have skinny 'pipes'. Phase 2 trials of several drugs in advanced stages. Appear hopeful. Focusing on diseases with wide applications.

Report this Post Replies: 0 | Reply

Featured Broker Partners